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Abstract
Dengue, Chikungunya and Zika are arboviruses transmitted by Ae. aegypti with 
significant public health impact. In the first trimester of 2015, autochthonous Zika 
transmission was reported in Mexico. The state of Yucatan is an endemic region 
where pregnant women with acute infection and related congenital abnormalities in 
fetus and newborns were observed. We describe results from a cohort of pregnant 
women and their babies followed up in Yucatan during the first Zika transmission 
outbreak (2016–2018). Clinical manifestations of acute ZIKV infection, persis-
tence of viral RNA in pregnant women, as well as congenital abnormalities were 
observed. In addition, we describe the phenotype of newborns from confirmed or 
suspected ZIKV prenatal infection.
Keywords: Zika infection, pregnant women birth defects, pregnancy,  
congenital Zika syndrome
1. Introduction
Dengue (DEN), Chikungunya (CHIK) and Zika (ZIKV) are arboviruses trans-
mitted by the mosquito Aedes aegypti and known as Aedes-borne-diseases. These 
diseases are associated with high morbidity and low mortality and considered 
a public health problem [1]. In the 2015, the ZIKV outbreak was considered an 
international emergency because infection in pregnant women was related to the 
increase of congenital abnormalities in the fetuses [2–4]. Vertical transmission of 
ZIKV was demonstrated by the RNA viral detection in placenta, amniotic fluid, 
serum and fetal brain in products with microcephaly, abortions or in autopsies of 
affected newborns and offspring of symptomatic or asymptomatic mothers [5, 6]. 
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The clinical manifestations of Zika in general population and pregnant women were 
mild rash, conjunctivitis and low fever, although up to 80% remain asymptomatic, 
higher than DEN (19%) and CHIK (45%) [1, 2, 7, 8].
ZIKV is a Flavivirus with an Asian and African lineages [9, 10]. Its RNA genome 
(10.8 kb) encodes for a 3419-amino acid polyprotein which form a capsid (C), a 
membrane precursor (prM), a wrap (E) and seven non-structural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5) [11]. ZIKV interferes with the neural 
development through decreased neural progenitor cells, arrest in neuronal migra-
tion and/or disruption of the maturation process of the fetus central nervous 
system (CNS) [12, 13]. The congenital Zika virus syndrome (CZVS) is a pattern of 
congenital defects associated with ZIKV infection during the pregnancy so ZIKV 
pathogenicity and virulence is currently studied [14–18].
The surveillance of ZIKV infection during pregnancy in endemic regions 
requires screening and detection of fetal morphological abnormalities [19]. An inte-
grated intervention model for the prevention of Zika and Aedes-borne diseases, that 
includes primary health care services, gynecologists, obstetricians, pediatricians, 
geneticists and neurologists should be mandatory. Strategies to prevent and control 
the vectors and reduce the risk for diseases transmission should be strengthened, 
particularly for protection of women in reproductive ages [20, 21].
Here we report final the clinical manifestations observed in a cohort of pregnant 
women and the congenital abnormalities in fetus and newborns during a Zika 
transmission period (2016–2018) in South Mexico.
2. Methods
We developed a prospective study to quantify the incidence of disease and infec-
tion in a cohort of pregnant women and newborns during an epidemic period of 
Zika (2016–2018). One of the main objectives of the study was to know the effect of 
prenatal exposure to ZIKV. The cohort included pregnant women, preferably in the 
first trimester of pregnancy. The follow up included clinical and molecular detec-
tion of ZIKV, DEN and CHIK. Obstetric ultrasound was performed to recognize 
morphological abnormalities in the fetuses.
During the development of this study, information on health care was pro-
vided to pregnant women and their partners, highlighting the importance of 
family planning and the use of condoms as a method to prevent the transmission 
of ZIKV, in addition to the implementation of measures to prevent the breeding of 
the Aedes aegypti and mosquito bites at home. We also provided information about 
general healthy habits, family planning and prevention of sexually transmitted 
diseases.
2.1 Study population
After the informed consent was signed, women were interviewed, and their 
medical records including periconceptional and pregnancy history, were collected. 
The recruitment included 884 families (3993 people) from the cities of Merida, 
Ticul, and Progreso de Castro in the Yucatan State, South-east Mexico [16]. Merida 
and its metropolitan area (≈1 million inhabitants), comprises ≈50% of the Yucatan 
population. Progreso de Castro (37,400) and Ticul (32,000) are smaller urban areas. 
We enrolled consenting pregnant women from these areas from July 1, 2016 to June 
2018 including pregnant women referred by physicians in primary care facilities or 
hospitals within the areas of our cohort study.
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2.2 Clinical follow-up of pregnant women
Patient monitoring included a monthly visit for clinical assessment and sample 
collection (blood and urine for RTC DEN/CHIK/ZIKV), weekly follow-up by 
text messages, and complete access to a telephone to report any clinical signs in 
pregnant women, their newborns, or any family contact. Tissues as umbilical cord 
blood, placental, amniotic fluid and breastmilk were collected, when possible for 
assessment of RT-PCR RNA ZIKV (TRIOPLEX) [22]. Other biochemical tests were 
performed to rule out Toxoplasma, Rubella, Cytomegalovirus, Herpes, Syphilis and 
HIV [23]. Depending of the mother or/and fetus risks, other test such as biochemi-
cal serum test and karyotype in amniotic fluid were taken. Ultrasound scanning was 
performed at the first contact and every 2 months. At the first visit, a questionnaire 
was fill up to establish the clinical-epidemiologic profile. The follow-up ended when 
the pregnancy was completed by delivery or fetal loss, or the participant withdrew 
from the study.
2.3 Clinical follow-up of newborns
Newborn follow up included: clinical evaluation (anthropometric measure-
ments, APGAR score and physical exam) and sample collection for RT-PCR for 
DEN/CHIK/ZIKV [20–22, 24]. Patients were followed up for 24 months of life 
for early recognition of morphological anomalies and recorded the neurological 
development. These evaluations included genetic, neurologic, ophthalmologic, and 
audiologic evaluation. Microcephaly was defined as a cranial circumference ≥2 SDs 
below the mean for the age and sex of the baby, following the recommendation of 
the World Health Organization [25–28].
2.4 Patients not initially integrated into the cohort
At the time when the cohort study was ongoing, in the Genetic Service in the 
center of Investigations Dr. Hideyo Noguchi/UADY received pregnant women 
with morphological abnormalities detected in their fetuses, or newborn patients in 
whom ZIKV prenatal infection was suspected. These patients were not integrated to 
the cohort, but a clinical follow-up was granted. Sample collections for RT-PCR for 
DEN/CHIK/ZIKV were offered.
3. Results
3.1 Pregnant women cohort
The study integrated 130 pregnant women with average age of 25 years. No 
major differences in age distribution and socioeconomic status between ZIKV-
positive and ZIKV-negative mothers were observed. Of all women, 40 (30%) were 
in the first trimester of pregnancy upon admission to the study, 62 (48%) in the 
second trimester and 28 (22%) in the third trimester (Table 1).
Positive results in blood/urine for ZIKV were found in 39 pregnant women, 31% 
(n = 13/39) at the first trimester, 52% (n = 20/39) in the second trimester and 15% 
(n = 6/39) in the third trimester.
Of 130 pregnant women, 39 (30%) were RNA-ZIKV positive at the time of the 
recruitment and 91 were negative (70%). From these, 11 (12% of initially RNA-
ZIKV negative) became positive during the surveillance.
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Of the 28 symptomatic patients (negative or positive ZIKV), the most common 
symptoms were exanthema (75%), pruritus (39%) and conjunctivitis (57%). Of 
the 21 patients with RT-PCR ZIKV-positive, 75% were symptomatic and 25% were 
asymptomatic. Even so, more than half (64%) of the women had at least, more 
than one sign or symptom compatible with an Aedes-borne acute infection. Most 
prevalent symptoms were exanthema (100%), conjunctivitis (76%), pruritus (52%) 
headache (50%), retro-orbital pain (55%), arthralgia (33%), hyperemia (22%) and 
joint edema (6%). No hemorrhagic or systemic complications were observed in 
any patient (Table 1). Differences in the distribution of ZIKV-positive vs. ZIKV-
negative women between the studied cities were not founded.
3.2 Persistence of ZIKV viral RNA in serum and urine in pregnant women
Of the 39 ZIKV-positive pregnant women, persistent RNA-ZIKV was detected 
in 38.5% (15/39) of the patients during 14 days after the initial symptoms or the last 
Total 
pregnant 
women
Positive for 
ZIKV in 
blood/urine
Negative 
for ZIKV in 
blood/urine
Trimester of pregnancy when enrolled 
pregnant women (130)
N:130 N:39 N:91 1st N:40 2nd N:62 3rd N:28
Mérida 75 (58%) 27 (69%) 47 (52%) 16 (40%) 37 (60%) 22 (79%)
Progreso 4 (3%) 0 4 (4) 0 2 (3%) 2 (7%)
Ticul 51 (39%) 12 (31%) 41 (44%) 24 (60%) 23 (37%) 4 (14%)
15–19 years 29 (22%) 8 (28%) 21 (72%) 6 (15%) 16 (26%) 7 (25%)
20–29 years 70 (54%) 22 (31%) 48 (69) 22 (55%) 34 (55%) 15 (54%)
30–39 years 30 (23%) 9 (23%) 21 (%) 12 (30%) 12 (19%) 6 (21%)
40–49 years 1 (1%) 0 1 (%) 0 0 1
Signs and 
symptoms
21/39 (%)
Exanthema 21/21 (100%)
Pruritus 11/21 (52%)
Joint edema 7/21 (33%)
Conjunctivitis 16/21 (76%)
Retro-orbital 
pain
10/21 (55%)
Hyperemia 5/21 (22%)
Clinical profile in 
persistence in serum 
samples
Total N:15 Symptomatic N:9 Asymptomatic p
Age (years) 24.7 ± 4.4 24.2 ± 3.3 23.8 ± 6 0.874
Persistence (days) 
(interval)
45.93 ± 24.4 (17–19) 50.11 ± 30.58 (17–97) 39.67 ± 9.89 (29–52) 0.363
Pregnancy trimester
First 6 (40%) 3 3
Second 8 (53%) 6 2
Third 1 (7%) 1
Table 1. 
Summary of health, medical and laboratory data collected from pregnant women in the cohort.
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PCR detection. Of these, six women were in the first trimester of gestation, eight in 
the second and one in the third. Within the group of symptomatic women (n = 28), 
nine (9/28) presented persistence of RNA-ZIKV, three in the first trimester and six 
Newborn 
residence
Merida N:67 Progreso N:2 Ticul N:46 Total births 
N:115
Percentile Percentile <3 N (%) Percentile 3–97 N 
(%)
Percentile >97 N 
(%)
Total
At birth End 
of the 
study
At 
birth
End of the 
study
At 
birth
End 
of the 
study
Birth weight 
percentiles
5 (4) 1 (1) 110 
(96)
114 (99) 0 (0) 0 (0) 115 (100)
Birth height 
percentiles
3 (3) 0 (0) 112 
(97)
115 (100) 0 (0) 0 (0) 115 (100)
Birth head 
circumference 
percentiles
2 (2) 1 (1) 112 
(97)
114 (99) 0 (0) 0 (0) 115 (100)
Newborn evaluations
From mothers ZIKV negative during 
pregnancy N:80
From mothers ZIKV positive 
during pregnancy N:35
N (%) Alterations N (%) N (%) Alterations 
N (%)
Newborn blood 29 (36) 27 (77)
Newborn urine 32 (40) 14 (40)
Pediatrics 39 (49) 30 (86)
Ophthalmology 19 (24) 31 (89) 3 (10)
Auditory 
screening
51 (64) 30 (86) 2 (7)
Placenta NA NA 17 (49)
Umbilical cord NA NA 17 (49)
Genetics NA NA 35 (100)
Metabolic 
screening
NA NA 34 (97)
Transfontanelar 
and abdominal 
ultrasound
NA NA 22 (63)
Age of newborns who completed the study
Age Mother ZIKV − Mother ZIKV + Total
1–6 months 16 (22%) 0 16 (16%)
7–12 months 25 (34%) 3 (10%) 28 (27%)
13–18 months 20 (27%) 17 (59%) 37 (36%)
19–23 months 12 (17%) 9 (31%) 21 (21%)
Total 73 29 102
Table 2. 
Newborn cohort follow-up.
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Patient/
sex
Mother Zika 
symptoms 
(MoG1)
WoG2 Neonatal head 
circumference  
(z score)
Birth weight for 
gestational age
Phenotype Intracranial 
calcification
Zika IgM InBios 
newborn/
mother6
Final diagnosis
1/Male No 38 Microcephaly (−3) Small Microcephaly 
MMC3
Yes −/− CZS/neural 
tube defect
2/Male Yes (2) 37 Normocephaly (10) Small IUGR4 NR5 −/− IUGR
3/Male No 38 Microcephaly (−3) Appropriated Microcephaly Yes −/− CZS
4/Male Yes (2) 37 Normocephaly (3) Small Asymptomatic NR −/− IgM positive for 
toxoplasma
5/Male No 33 Normocephaly (10) Appropriated Microcephaly 
Arthrogryposis
Yes Positive in 
serum/−
CZS
6/Male No 39 Microcephaly (−3) Appropriated Microcephaly Yes −/− CZS
7/Female Yes (2) 40 Normocephaly (3) Small Postnatal 
microcephaly
NR −/− CZS
8/Female No 38 Macrocephaly (97) Appropriated Macrocephaly 
Arthrogryposis
Normal −/− Amyoplasia 
congenital
1Month of gestation.
2Weeks of gestation.
3Myelomeningocele.
4Intrauterine growth retardation.
5NR: not reported.
6Serum and urine were taken at born in newborns and theirs mothers.
Table 3. 
Main findings of eight patients evaluated for suspected ZIKV prenatal infection.
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in the second. Of these, 100% (9/9) presented rash, 55% (5/9) conjunctivitis and 
33.3% (2/9) fever. Only 22.2% (2/28) reported having three symptoms, fever, rash 
and conjunctivitis (Table 1).
3.3 Newborn evaluations
All pregnancies of women in the cohort have ended the pregnancy. Two fetal 
losses (one in the first trimester and one in the third trimester) occurred in ZIKV-
negative mothers. Of all newborns alive, 3% were preterm (two in ZIKV-negative 
mothers and one in a ZIKV-positive moth group). No newborns or products of 
conception were positive for RNA-ZIKV. Clinical evaluation of Apgar scores in the 
newborns did not show significant differences between positive/negative ZIKV 
mothers. Also, microcephaly was not founded in any newborn. One newborn of 
Zika-positive mother died the first days of life due to gastroschisis (Table 2).
During the ZIKV epidemiological period in Yucatan, 10 patients attended 
the medical genetics clinic in CIR Hideyo Noguchi with a reference diagnosis of 
microcephaly, arthrogryposis and/or ventriculomegaly. Two of them were excluded 
from the follow up because ZIKV prenatal symptoms were absent in the mothers 
and microcephaly and intracranial calcifications were discarded in the patients. 
Preconceptional, prenatal and perinatal backgrounds were investigated in all patients. 
Only one woman took folic acid 6 months before the conception and none used 
mosquito repellent during pregnancy, even they were living in an endemic region.
Of the newborns evaluated, clinical symptoms of Zika were reported only in 
two mothers in the first trimester of gestation, but only one was tested positive for 
RT-PCR Zika. One more woman reported symptoms of Zika 1 month before concep-
tion. During the pregnancy, intrauterine growth restriction in 4/8 (50%) and oligo-
hydramnios in 2/8 (25%) were reported. Only one patient was reported prenatally 
with microcephaly, intracranial calcifications and ventriculomegaly (patient 5)  
(Table 3). Five pregnancies were ended by caesarean section and three by vaginal 
delivery between second semester of 2016 and the second semester of 2017.
All newborns were at term, except one. Of them, six were males and two were 
females. Three males had microcephaly with less than three standard deviations 
and one male with microcephaly less than two standard deviations. One female 
had macrocephaly. All babies from the three mothers with positive ZIKV symp-
toms during o before pregnancy were born with normocephaly, but were small for 
gestational age. One of these babies, a female, developed microcephaly within the 
first 6 months of life. Of all babies follow up, two had arthrogryposis, one with 
microcephaly and one with macrocephaly. Both of them were child from non-
symptomatic mothers. Only five patients were evaluated with axial computerized 
tomography with positive intracranial calcifications founded in four. All of them 
were from asymptomatic mothers.
All patients and their mothers were tested for RT-PCR for ZIKV/DEN/CHIK in 
serum and urine. TORCH was also performed. RNA-ZIKV was obtained only in 
serum of one male with microcephaly, arthrogryposis and intracranial calcifica-
tions. This male was from an asymptomatic mother. Antibodies IgM of toxoplasma 
were detected in one asymptomatic male whom has clinical symptoms of Zika 
during first trimester of pregnancy.
4. Discussion
The WHO declared the ZIKV outbreak in South America and the associated 
increase in neurological disorders and neonatal malformations a “public health 
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emergency of international concern” [2], and the CDC issued the ZIKV epidemiologi-
cal alert, recommendations of high-risk Mexican territories was recognized by the 
National Health Service. Even so, the recognition of the ZIKV infection symptoms 
by patients and health workers, were underestimated [29]. In Mexico, first patients 
with ZIKV infection were documented early in 2016 even so, captured mosquitoes 
in early 2015 were recognized with ZIKV infection [30].
After the observed relationship between prenatal Zika infection and the risk of 
congenital defects in Brazil and Colombia, we realized a cohort with detailed evalu-
ation of pregnant women searching ZIKV infection and congenital abnormalities 
[1, 31, 32].
The women in this study with the highest proportion of symptoms with ZIKV 
were those from 20 to 29 years, different from other studies that have reported 
the highest symptomatic disease ratio among women >30 years of age [33, 34]. In 
our studies this can be explained because the highest incidence of pregnancies in 
women was aged 20–29 years [1]. In clinically affected women, univariate analyzes 
showed that the most sensitive clinical sign was the exanthema, but it was also the 
least specific. The triad, conjunctival hyperemia, joint edema and exanthema had 
the highest level of specificity [35].
In pregnant women with exanthema without fever or other symptoms should 
to suspect ZIKV infection. In this study, ZIKV/DEN/CHIK co-infection was not 
identified neither [36].
The persistence of RNA viral in pregnant women has been described previously, 
reported a patient positive for RNA-ZIKV until 10 weeks after the onset of symp-
toms. In this study, the maximum viremia persistence was 97 days, but a quarter 
of positive mothers had viremia for more than 8 weeks [37]. From all RNA ZIKV-
positive mothers, only 50% of the symptomatic group had persistence of ZIKV for 
more than 8 weeks. Other series reported longer RNA ZIKV viremia in symptomatic 
women than asymptomatic and other study obtained similar results in serum, in a 
range of 14–63 days; although in this study, we detected two pregnant women who 
had viremia older than 90 days [33, 34]. A study reported viral persistence in five 
pregnant women, of which 80% were symptomatic and only one case was asymp-
tomatic. In this study, a higher percentage of asymptomatic viral persistence cases 
were found with 40%. In the symptomatic group, the average number of days of 
persistence after the onset of symptoms was greater than that reported, no relation-
ship was observed between viral persistence and the presence of abnormalities in 
pregnancy products [38, 39].
The confirmatory tests which provide evidence for prenatal infection by ZIKV 
were conducted based on tests in the mother and the newborn were made with 
viral RNA isolated from biological fluids and placental tissues performed with the 
Trioplex kit of the CDC. The ZIKV genome was detected in cerebrospinal fluid, car-
diac fluid, chorionic villi, fetal face of the placenta, serum and urine [26]. Vertical 
transmission studying the placental and fetus tissue also failed been demonstrated 
[40, 41].
Clinical variability in patients in whom ZIKV infection were prenatally sus-
pected was described previously, in this cohort, congenital abnormalities associated 
to ZIKV were not observed in fetus, stillborn or newborns [1, 17]. Only one patient 
with gastroschisis was detected but the prenatal ZIKV infection in her mother was 
after detection of this abnormality.
Congenital Zika syndrome (CSZ) was observed in the patients evaluated from 
the Genetics Service out of the initial cohort. In them, Zika symptoms in mothers, 
microcephaly, arthrogryposis and intracranial calcifications were observed as in 
other reports [1, 17, 18]. Establishing the final diagnosis of ZIKV prenatal infection 
was difficult especially in asymptomatic mothers or in mild affected babies [31]. 
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In two patients, the final diagnosis was toxoplasma and congenital amyoplasia. 
Asymptomatic or mild symptomatic women would be a seriously limitation from 
early ZIKV infection. To define diagnostic of prenatal ZIKV is important: (1) to 
establish the follow up of the affected patient, (2) to limit the tests related to others 
genetic diseases that share symptoms with CSZ and (3) to establish the specific 
risk of recurrences of congenital abnormalities in subsequent pregnancies in the 
mother.
5. Conclusions
In this study, symptomatic or asymptomatic pregnant women with a high 
prevalence for ZIKV are reported, however there was no positive newborn or with 
malformations associated with ZIKV, despite the genetic consultation, the pres-
ence of CSZ, laboratory-confirmed if present so doctors should maintain a realistic 
perspective of the impact of ZIKV on pregnancy. And despite the uncertainties, 
future mothers should receive adequate, systematic advice and the best planned 
obstetric surveillance, always considering the gestational moment of maternal 
ZIKV infection and accept that there is gestational risk for different elements of the 
CZS phenotype in risk areas ZIKV transmission.
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